SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...

The move to the dose-expansion cohort follows earlier findings from the dose-escalation stage.

Silexion Therapeutics (SLXN) said Wednesday it has initiated its phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, adding that the clinical site is now cleared to commence ...

Key Points Interested in Altimmune, Inc.? Here are five stocks we like better. Altimmune's Phase II RECLAIM trial met its ...

A dual GLP-1 and glucagon agonist developed by Altimmune has been shown to reduce drinking in people with alcohol use ...

Altimmune said it plans to request an end-of-Phase 2 meeting with the U.S. Food and Drug Administration based on the top-line results from its trial evaluating pemvidutide, a balanced glucagon/GLP-1 ...

Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...

EMERYVILLE, Calif.-- (BUSINESS WIRE)--Jul 29, 2026-- ...

When Is the Right Time? A Qualitative Study of Timing of Specialty Palliative Care in Patients With Brain Tumors Phase II trials are intended to identify promising treatment paradigms for definitive ...